No Data
Express News | Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2B Rezilient1 Study of Zipalertinib
Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1 clinical trial.
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed,
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28
H.C. Wainwright analyst Edward White maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 3
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination With a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung
104016428 : will that mean that after their presentation on June 1 it might fly high on monday? or when the news is out for ASCO that's the end of the rally